The integration of theoretical and experimental approaches and data with modern simulation tools and other computer-assisted methods has the potential to sustainably revolutionize the development of novel pharmaceutical products by decreasing development time and reducing costs.
Our research has the following focus:
‘Digital Design’ or ‘in-silico design’ have become indispensable for most high-tech industries. This is not yet the case for the pharmaceutical sector. Requirements in computational power, complex interactions and interdependencies as well as missing fundamental process understanding have hindered the application.
Through the combination and integration of self-developed algorithms, software tools and other commercial products the RCPE enables the simulation of single-unit operations and process chains for granular/fluid media. This way we can visualize latent process phenomena, identify opportunities for optimization and are able to directly test various process parameters.
Present approaches to formulation often rely on experience respectively statistical and semi-mechanistic approaches. The missing integration and combination of material properties, simulation and processability extends development processes and limits the exploitation of efficiency and innovation potentials.
At RCPE we combine our capabilities in material and analytical science, modeling and simulation as well as process science to provide pharmaceutical companies a foundation for rational formulation design. Using just several grams of material we can pinpoint behavior and processability and therefore the stability and performance of the final product.
The best pharmaceutical molecule is rendered useless if it doesn’t arrive where it needs to be. In biopharmaceutics we concentrate on the correlation between chemical respectively physical properties of a pharmaceutical product, its dosage form, the application route and the intended absorption. By systematically integrating of in-vitro experiments and in-silico characterization tools, we develop in-silico physiologically-based mechanistic models to understand, predict and optimize key performance indicators of oral, inhalative an intravaginal products.
LEADING PHARMA INNOVATION
